Elutia (ELUT) Return on Capital Employed (2020 - 2026)
Elutia's (ELUT) quarterly Return on Capital Employed came in at 79.85% in Q1 2026, up 362531.0% year-on-year from N/an in Q1 2025, and up 41.73% quarter-over-quarter from 137.04% in Q4 2025.
Elutia (ELUT) Return on Capital Employed (2020 - 2026) Analysis & Trends
Elutia has disclosed Return on Capital Employed across 7 years of filings, most recently posting 79.85% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 79.85%, up 362531.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 79.85% (up 362531.0% YoY), and the FY2025 annual result was 111.67%, up 143749.0% from the prior year.
- Return on Capital Employed came in at 79.85% for Q1 2026 at Elutia, up from 137.04% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2797.28% in Q2 2024 to a low of 3705.17% in Q1 2025.
- The 5-year median for Return on Capital Employed is 150.55% (2022), against an average of 230.18%.
- Across the five-year window, Return on Capital Employed slumped 215906 bps in 2024 and jumped 362531 bps in 2026, its largest moves.
- Elutia's Return on Capital Employed stood at 150.55% in 2022, then slumped by 240 bps to 511.6% in 2023, then slumped by 47 bps to 751.83% in 2024, then jumped by 82 bps to 137.04% in 2025, then surged by 42 bps to 79.85% in 2026.
- The last three Return on Capital Employed figures came in at 79.85% (Q1 2026), 137.04% (Q4 2025), and 302.06% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | Elutia | 45.15 Mn | 16.66 Mn | 1.80 Mn | -79.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.85% |
| Dec 31, 2025 | -137.04% |
| Sep 30, 2025 | 302.06% |
| Jun 30, 2025 | 2,421.61% |
| Mar 31, 2025 | -3,705.17% |
| Dec 31, 2024 | -751.83% |
| Sep 30, 2024 | -632.99% |
| Jun 30, 2024 | 2,797.28% |
| Mar 31, 2024 | -2,309.26% |
| Dec 31, 2023 | -511.60% |
| Sep 30, 2023 | -361.83% |
| Jun 30, 2023 | -243.47% |
| Mar 31, 2023 | -150.20% |
| Dec 31, 2022 | -150.55% |
| Sep 30, 2022 | -189.82% |
| Jun 30, 2022 | -137.90% |
| Mar 31, 2022 | -72.47% |
| Dec 31, 2021 | -61.36% |
| Sep 30, 2021 | -45.48% |
| Jun 30, 2021 | -30.91% |